Adversarial verification is the cost of being early.
Biopharma decisions move on intelligence that is increasingly machine-generated and decreasingly source-cited. There is no hallucination tolerance for an investment committee allocating against a thesis, a ministry procuring at sovereign scale, or a regulator interpreting evidence. AimwellBio is the verified intelligence layer underneath those decisions — every signal carrying provenance, every brief audited by four independent agents, every output traceable to its evidentiary chain. The wound-care vertical is the first proof: $12–15B repricing inside the 2025–2026 CMS LCD cycle, an 18-month adverse-event lag between PubMed signal and FDA action, and a Saudi Vision 2030 procurement window where sovereign decisions will be defended on the citation, not the model.
Four operating principles separate AimwellBio from generative-research tools, sell-side research, and consumer LLM products. Each pillar is enforced architecturally, not aspirationally.
Every signal carries provenance: source URL, fetch timestamp, source method. No hallucination tolerance for ministry-grade decisions. If a claim cannot be traced to its origin, it does not enter the brief.
Pipelines per indication — wound-care first, diabetes next, then oncology, then rare-disease. Same architecture, different scope. Re-runnable. Citeable. Defensible against adversarial diligence.
Four independent audit agents check every brief before it leaves the platform. Confidence framework: source-backed > pattern-inferred > model-hypothesis > speculative. Visible on every card.
Built for KSA Vision 2030, EU regulators, FDA, CMS, and global pharma decision committees. Not for retail. The audience determines the standard, and the standard is ministry-grade by default.
The Advanced Wound Intelligence Report is the first vertical built on AimwellBio's pipeline. Embedded below is the print-rendered investor brief — 86 source-cited signals across PubMed, ClinicalTrials.gov, and SEC, 30 companies under continuous coverage, and the regulatory pulse on the 2025–2026 CMS LCD cycle.
AimwellBio's durable asset is not any single report. It is tools/scout-ingest/ — a Python ingest pipeline that fetches, normalizes, dedupes, and source-cites intelligence across FDA openFDA, ClinicalTrials.gov, PubMed, SEC EDGAR, CMS LCD, USPTO, and manufacturer pipeline pages. ToS-compliant. Rate-limited. Re-runnable.
Wound care is Pipeline #1. Diabetes, oncology, rare-disease, and neurology are the same architecture with a different --indication flag. Each new vertical inherits provenance, adversarial audit, and indication-aware tagging by default. Each new vertical compounds the moat.
When the pipeline runs, intelligence refreshes. The report is just a window onto the work.
Saudi Arabia carries an 18% diabetes prevalence and has positioned lower-extremity amputation reduction as a stated Vision 2030 priority. Procurement at this scale will not be defended on a generative summary. It will be defended on the citation, the source method, and the audit trail.
AimwellBio is purpose-built for that defense. The same infrastructure that gives an investment committee defensible diligence gives a ministry defensible procurement. Partnership routes are open for sovereign health systems, EU regulators, and global pharma decision committees operating at or above ministry-grade evidence standards.
Discuss sovereign deployment →